• UK EIS qualifying, clinical stage Biotech company founded by Nobel Prize winner Professor Sir Martin Evans, developing innovative heart failure medicines

• Expert team led by Executive Chairman Dr Darrin Disley OBE including seasoned executives with a track record of developing medicines and securing exits   

• Lead program in heart failure with long-term Phase 2 data with best-in-class target product profile including disease modifying efficacy and low cost of goods 

• Leading patent portfolio with ~100 granted and pending US, EU, Asia and ROW patents

• Track-record of securing US FDA, EU and UK clinical trial and GMP Manufacturing approvals 

• Manufacturing and laboratory facilities in UK and Europe enabled highly efficient, low cost GMP manufacturing for US, UK, EU and Asian markets 

• Strategic investor base includes Big Pharma, Biotech VCs and UK and US institutional investors

Product and Technology Platform

• Lead program in heart failure with long-term Phase 2 data protected with granted US, EU, Asia and ROW patents 

• Product portfolio includes lead program and two fast followers addressing compelling niches in the high value (£12B), high growth (10% CAGR) heart failure market

• Portfolio developed in-house from a proprietary tissue engineering platform allowing the development of novel allogeneic cell therapies

• Proprietary manufacturing technology enabled highly efficient, low cost GMP manufacturing for US, UK, EU and Asian markets 

Product pipeline

• CLXR-001: Compelling efficacy and safety data in completed P2a clinical trial 

• CLXR-001 currently in randomised EU PI/II trial 

• CLXR-002 and CLXR-003 address high value moderate heart failure market with minimally invasive delivery 

• CLXR-004 for use in combination with LVAD device to treat sever heart failure orphan disease indication